Manuscripts

1. Girvan AC, Teng Y, Casson LK, Thomas SD, Juliger S, Ball MW, Klein JB, Pierce WM, Jr., Barve SS, Bates PJ. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol Cancer Ther.5(7):1790-9. Jul 2006

2. Asmus SE, Anderson EK, Ball MW, Barnes BA, Bohnen AM, Brown AM, Hartley LJ, Lally MC, Lundblad TM, Martin JB, Moss BD, Phelps KD, Phillips LR, Quilligan CG, Steed RB, Terrell SL, Warner AE. Neurochemical characterization of tyrosine hydroxylase-immunoreactive interneurons in the developing rat cerebral cortex. Brain Res.1222:95-105. Jul 30 2008

3. Mullins JK, Guzzo TJ, Ball MW, Pierorazio PM, Eifler J, Jarrett TW, Schoenberg MP, Bivalacqua TJ. Ureteral stents placed at the time of urinary diversion decreases postoperative morbidity. Urol Int.88(1):66-70. 2012

4. Reese AC, Ball MW, Efron JE, Chang A, Meyer C, Bivalacqua TJ. Favorable response to neoadjuvant chemotherapy and radiation in a patient with prostatic stromal sarcoma. J Clin Oncol.30(33):e353-5. Nov 20 2012

5. Wang H, Albadine R, Magheli A, Guzzo TJ, Ball MW, Hinz S, Schoenberg MP, Netto GJ, Gonzalgo ML. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urol Oncol.30(4):428-33. Jul-Aug 2012

6. Ball MW, Allaf ME. Editorial comment for Kaplan et al. J Endourol.27(9):1100-1. Sep 2013

7. Ball MW, Gorin MA, Allaf ME. Reducing morbidity of pelvic and retroperitoneal lymphadenectomy. Curr Urol Rep.14(5):488-95. Oct 2013

8. Cohen J, Jayram G, Mullins JK, Ball MW, Allaf ME. Do fibrin sealants impact negative outcomes after robot-assisted partial nephrectomy? J Endourol.27(10):1236-9. Oct 2013

9. Gorin MA, Ball MW, Pierorazio PM, Tanagho YS, Bhayani SB, Kaouk JH, Rogers CG, Stifelman MD, Khalifeh A, Kumar R, Sivarajan G, Allaf ME. Outcomes and predictors of clinical T1 to pathological T3a tumor up-staging after robotic partial nephrectomy: a multi-institutional analysis. J Urol.190(5):1907-11. Nov 2013

10. Ball MW, Allaf ME. Robot-assisted adrenalectomy (total, partial, & metastasectomy). Urol Clin North Am.41(4):539-47. Nov 2014

11. Ball MW, Mullins JK, Epstein JI, Partin AW, Walsh PC. Re: detailed analysis of patients with metastasis to the prostatic anterior fat pad lymph nodes: a multi-institutional study: I. Y. Kim, P. K. Modi, E. Sadimin, Y.-S. Ha, J. H. Kim, D. Skarecky, D. Y. Cha, C. O. Wambi, Y.-C. Ou, B. Yuh, S. Park, E. Llukani, D. M. Albala, T. Wilson, T. Ahlering, K. Badani, H. Ahn, D. I. Lee, M. May, W.-J. Kim and d. H. Lee J Urol 2013;190:527-534. J Urol.191(2):559. Feb 2014

12. Faisal FA, Sundi D, Pierorazio PM, Ball MW, Humphreys EB, Han M, Epstein JI, Partin AW, Carter HB, Bivalacqua TJ, Schaeffer EM, Ross AE. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature. BJU Int.114(6b):E120-E29. Dec 2014

13. Harris KT, Ball MW, Gorin MA, Curtiss KM, Pierorazio PM, Allaf ME. Transperitoneal robot-assisted partial nephrectomy: a comparison of posterior and anterior renal masses. J Endourol.28(6):655-9. Jun 2014

14. Patel HD, Kates M, Pierorazio PM, Gorin MA, Jayram G, Ball MW, Hyams ES, Allaf ME. Comorbidities and causes of death in the management of localized T1a kidney cancer. Int J Urol.21(11):1086-92. Nov 2014

15. Patel HD, Kates M, Pierorazio PM, Hyams ES, Gorin MA, Ball MW, Bhayani SB, Hui X, Thompson CB, Allaf ME. Survival after diagnosis of localized T1a kidney cancer: current population-based practice of surgery and nonsurgical management. Urology.83(1):126-32. Jan 2014

16. Rahbar H, Bhayani S, Stifelman M, Kaouk J, Allaf M, Marshall S, Zargar H, Ball MW, Larson J, Rogers C. Evaluation of renal mass biopsy risk stratification algorithm for robotic partial nephrectomy--could a biopsy have guided management? J Urol.192(5):1337-42. Nov 2014

17. Reese AC, Ball MW, Gandhi N, Gorin MA, Netto GJ, Bivalacqua TJ, Schoenberg MP. The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer. Urology.84(2):358-63. Aug 2014

18. Sundi D, Wang VM, Pierorazio PM, Han M, Bivalacqua TJ, Ball MW, Antonarakis ES, Partin AW, Schaeffer EM, Ross AE. Very-high-risk localized prostate cancer: definition and outcomes. Prostate Cancer Prostatic Dis.17(1):57-63. Mar 2014

19. Zargar H, Bhayani S, Allaf ME, Stifelman M, Rogers C, Larson J, Ball MW, Marshall S, Kumar R, Fergany A, Campbell S, Kaouk J. Comparison of perioperative outcomes of robot-assisted partial nephrectomy and open partial nephrectomy in patients with a solitary kidney. J Endourol.28(10):1224-30. Oct 2014

20. Ball MW, Allaf ME. Robotic adrenalectomy: the jury is still out. Gland Surg.4(4):277-8. Aug 2015

21. Ball MW, Bezerra SM, Gorin MA, Cowan M, Pavlovich CP, Pierorazio PM, Netto GJ, Allaf ME. Grade heterogeneity in small renal masses: potential implications for renal mass biopsy. J Urol.193(1):36-40. Jan 2015

22. Ball MW, Gorin MA, Bhayani SB, Rogers CG, Stifelman MD, Kaouk JH, Zargar H, Marshall S, Larson JA, Rahbar HM, Trock BJ, Pierorazio PM, Allaf ME. Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: a multi-institutional analysis. Urol Oncol.33(3):112 e9-14. Mar 2015

23. Ball MW, Gorin MA, Jayram G, Pierorazio PM, Allaf ME. Robot-assisted radical nephrectomy with inferior vena cava tumor thrombectomy: technique and initial outcomes. Can J Urol.22(1):7666-70. Feb 2015

24. Ball MW, Partin AW, Epstein JI. Extent of extraprostatic extension independently influences biochemical recurrence-free survival: evidence for further pT3 subclassification. Urology.85(1):161-4. Jan 2015

25. Ball MW, Reese AC, Mettee LZ, Pavlovich CP. Safety of minimally invasive radical prostatectomy in patients with prior abdominopelvic or inguinal surgery. J Endourol.29(2):192-7. Feb 2015

26. Ball MW, Sundi D, Reese AC, Meyer CF, Terezakis SA, Efron JE, Schoenberg MP, Epstein JI, Ahuja N, Bivalacqua TJ. Multimodal Therapy in the Treatment of Prostate Sarcoma: The Johns Hopkins Experience. Clin Genitourin Cancer.13(5):435-40. Oct 2015

27. Bezerra SM, Chaux A, Ball MW, Faraj SF, Munari E, Gonzalez-Roibon N, Sharma R, Bivalacqua TJ, Burnett AL, Netto GJ. Human papillomavirus infection and immunohistochemical p16(INK4a) expression as predictors of outcome in penile squamous cell carcinomas. Hum Pathol.46(4):532-40. Apr 2015

28. Cohen JE, Landis P, Trock BJ, Patel HD, Ball MW, Auwaerter PG, Schaeffer E, Carter HB. Fluoroquinolone resistance in the rectal carriage of men in an active surveillance cohort: longitudinal analysis. J Urol.193(2):552-6. Feb 2015

29. Curtiss KM, Ball MW, Gorin MA, Harris KT, Pierorazio PM, Allaf ME. Perioperative outcomes of robotic partial nephrectomy for intrarenal tumors. J Endourol.29(3):293-6. Mar 2015

30. Gordetsky J, Gorin MA, Canner J, Ball MW, Pierorazio PM, Allaf ME, Epstein JI. Frozen section during partial nephrectomy: does it predict positive margins? BJU Int.116(6):868-72. Dec 2015

31. Gorin MA, Ball MW, Pierorazio PM, Argani P, Allaf ME. Partial nephrectomy for the treatment of translocation renal cell carcinoma. Clin Genitourin Cancer.13(3):e199-201. Jun 2015

32. Harris KT, Ball MW, Gorin MA, Allaf ME, Pierorazio PM. Outcomes of partial nephrectomy in patients who meet percutaneous ablation criteria. Cent European J Urol.68(2):132-6. 2015

33. Harris KT, Ball MW, Pierorazio PM. Author's Reply. Cent European J Urol.68(2):140. 2015

34. Harris KT, Gorin MA, Ball MW, Pierorazio PM, Allaf ME. A comparative analysis of robotic vs laparoscopic retroperitoneal lymph node dissection for testicular cancer. BJU Int.116(6):920-3. Dec 2015

35. Harris KT, Shaikh SA, Ball MW, Allaf ME, Pierorazio PM. Management of Metachronous Bilateral Testis Cancer in a Patient with Pre-B Cell ALL. Case Rep Urol.2015:646875. 2015

36. Kates M, Ball MW, Patel HD, Gorin MA, Pierorazio PM, Allaf ME. The financial impact of robotic technology for partial and radical nephrectomy. J Endourol.29(3):317-22. Mar 2015

37. Larson JA, Kaouk JH, Stifelman MD, Rogers CG, Allaf ME, Potretzke A, Marshall S, Zargar H, Ball MW, Bhayani SB. Nonmodifiable factors and complications contribute to length of stay in robot-assisted partial nephrectomy. J Endourol.29(4):422-9. Apr 2015

38. Ludwig WW, Gorin MA, Ball MW, Schaeffer EM, Han M, Allaf ME. Instrument Life for Robot-assisted Laparoscopic Radical Prostatectomy and Partial Nephrectomy: Are Ten Lives for Most Instruments Justified? Urology.86(5):942-5. Nov 2015

39. Patel HD, Ball MW, Cohen JE, Kates M, Pierorazio PM, Allaf ME. Morbidity of urologic surgical procedures: an analysis of rates, risk factors, and outcomes. Urology.85(3):552-9. Mar 2015

40. Pierorazio PM, Johnson MH, Ball MW, Gorin MA, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol.68(3):408-15. Sep 2015

41. Rowe SP, Gorin MA, Gordetsky J, Ball MW, Pierorazio PM, Higuchi T, Epstein JI, Allaf ME, Javadi MS. Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma. Clin Nucl Med.40(4):309-13. Apr 2015

42. Zargar H, Allaf ME, Bhayani S, Stifelman M, Rogers C, Ball MW, Larson J, Marshall S, Kumar R, Kaouk JH. Trifecta and optimal perioperative outcomes of robotic and laparoscopic partial nephrectomy in surgical treatment of small renal masses: a multi-institutional study. BJU Int.116(3):407-14. Sep 2015

43. Ball MW. Editorial Comment to Urinary tract infection-like symptom is associated with worse bladder cancer outcomes in the Medicare population: Implications for sex disparities. Int J Urol.23(1):48. Jan 2016

44. Ball MW, Allaf ME. Editorial Comment. J Urol.196(2):333. Aug 2016

45. Ball MW, Allaf ME. Reply to Valerian Ciprian Lucan, Salvatore Buttice, Rosa Pappalardo, Carlo Magno's Letter to the Editor re: Mark W. Ball, Nathaniel Readal, Phillip M. Pierorazio, Mohamad E. Allaf. Splitting One Kidney into Two: Robotic Partial Kidney Transplant in a Porcine Model. Eur Urol 2016;69:968-9. Eur Urol.70(3):e82. Sep 2016

46. Ball MW, Allaf ME, Drake CG. Recent advances in immunotherapy for kidney cancer. Discov Med.21(116):305-13. Apr 2016

47. Ball MW, Bezerra SM, Chaux A, Faraj SF, Gonzalez-Roibon N, Munari E, Sharma R, Bivalacqua TJ, Netto GJ, Burnett AL. Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression. Urology.92:51-6. Jun 2016

48. Ball MW, Gorin MA, Guner G, Pierorazio PM, Netto G, Paller CJ, Hammers HJ, Diaz LA, Allaf ME. Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study. Clin Genitourin Cancer.14(5):e515-e20. Oct 2016

49. Ball MW, Gorin MA, Harris KT, Curtiss KM, Netto GJ, Pavlovich CP, Pierorazio PM, Allaf ME. Extent of renal vein invasion influences prognosis in patients with renal cell carcinoma. BJU Int.118(1):112-7. Jul 2016

50. Ball MW, Nathan R, Gerayli F. Long-Term Response After Surgery and Adjuvant Chemoradiation for T4 Mucinous Adenocarcinoma of the Bladder: A Case Report and Review of the Literature. Clin Genitourin Cancer.14(2):e225-7. Apr 2016

51. Ball MW, Readal N, Pierorazio PM, Allaf ME. Splitting One Kidney into Two: Robotic Partial Kidney Transplant in a Porcine Model. Eur Urol.69(5):968-9. May 2016

52. Gorin MA, Rowe SP, Baras AS, Solnes LB, Ball MW, Pierorazio PM, Pavlovich CP, Epstein JI, Javadi MS, Allaf ME. Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. Eur Urol.69(3):413-6. Mar 2016

53. Helmers MR, Ball MW, Gorin MA, Pierorazio PM, Allaf ME. Robotic versus laparoscopic radical nephrectomy: comparative analysis and cost considerations. Can J Urol.23(5):8435-40. Oct 2016

54. Kates M, Ball MW, Chappidi MR, Baras AS, Gordetsky J, Sopko NA, Brant A, Pierorazio PM, Epstein JI, Schoenberg MP, Bivalacqua TJ. Accuracy of urethral frozen section during radical cystectomy for bladder cancer. Urol Oncol.34(12):532 e1-32 e6. Dec 2016

55. Ko JS, Readal N, Ball MW, Han M, Pierorazio PM. Call Schedule and Sleep Patterns of Urology Residents Following the 2011 ACGME Reforms. Urol Pract.3(2):147-52. Mar 2016

56. An JY, Ball MW, Gorin MA, Hong JJ, Johnson MH, Pavlovich CP, Allaf ME, Pierorazio PM. Partial vs Radical Nephrectomy for T1-T2 Renal Masses in the Elderly: Comparison of Complications, Renal Function, and Oncologic Outcomes. Urology.100:151-57. Feb 2017

57. Ball MW. Partial prostatectomy: technically feasible, but patient selection is paramount. Transl Androl Urol.6(2):308-09. Apr 2017

58. Ball MW. Editorial Comment. Urology.101:175-76. Mar 2017

59. Ball MW. Surgical management of metastatic renal cell carcinoma. Discov Med.23(129):379-87. Jun 2017

60. Ball MW. Editorial Comment. J Urol.198(6):1352. Dec 2017

61. Ball MW, Gorin MA, Drake CG, Hammers HJ, Allaf ME. The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas. Eur Urol Focus.3(6):584-89. Dec 2017

62. Ball MW, Harris KT, Schwen ZR, Mullins JK, Han M, Walsh PC, Partin AW, Epstein JI. Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series. BJU Int.119(3):444-48. Mar 2017

63. Ball MW, Hemal AK, Allaf ME. International Consultation on Urological Diseases and European Association of Urology International Consultation on Minimally Invasive Surgery in Urology: laparoscopic and robotic adrenalectomy. BJU Int.119(1):13-21. Jan 2017

64. Ball MW, Pierorazio PM. Reply by the Authors. Urology.103:274. May 2017

65. Ball MW, Ross AE, Ghabili K, Kim C, Jun C, Petrisor D, Pan L, Epstein JI, Macura KJ, Stoianovici DS, Allaf ME. Safety and Feasibility of Direct Magnetic Resonance Imaging-guided Transperineal Prostate Biopsy Using a Novel Magnetic Resonance Imaging-safe Robotic Device. Urology.109:216-21. Nov 2017

66. Ball MW, Schwen ZR, Ko JS, Meyer A, Netto GJ, Burnett AL, Bivalacqua TJ. Lymph node density predicts recurrence and death after inguinal lymph node dissection for penile cancer. Investig Clin Urol.58(1):20-26. Jan 2017

67. Ball MW, Singer EA, Srinivasan R. Renal cell carcinoma: molecular characterization and evolving treatment paradigms. Curr Opin Oncol.29(3):201-09. May 2017

68. Cocks M, Taheri D, Ball MW, Bezerra SM, Del Carmen Rodriguez M, Ricardo BFP, Bivalacqua TJ, Sharma RB, Meeker A, Chaux A, Burnett AL, Netto GJ. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. Hum Pathol.59:55-61. Jan 2017

69. De Bari B, Stish B, Ball MW, Habboush Y, Sargos P, Krengli M, Bossi A, Stabile A, Sole Pesutic C, Lestrade L, Smeenk RJ, Jereczek-Fossa BA, Zilli T, Crehange G, Alongi F, Zaorsky N, Ozsahin M. Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study. Prostate.77(10):1160-66. Jul 2017

70. Falegan OS, Ball MW, Shaykhutdinov RA, Pieroraio PM, Farshidfar F, Vogel HJ, Allaf ME, Hyndman ME. Urine and Serum Metabolomics Analyses May Distinguish between Stages of Renal Cell Carcinoma. Metabolites.7(1). Feb 3 2017

71. Kostibas MP, Arora V, Gorin MA, Ball MW, Pierorazio PM, Allaf ME, Nyhan D, Brady MB. Defining the Role of Intraoperative Transesophageal Echocardiography During Radical Nephrectomy With Inferior Vena Cava Tumor Thrombectomy for Renal Cell Carcinoma. Urology.107:161-65. Sep 2017

72. Rowe SP, Gorin MA, Solnes LB, Ball MW, Choudhary A, Pierorazio PM, Epstein JI, Javadi MS, Allaf ME, Baras AS. Correlation of (99m)Tc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression. EJNMMI Res.7(1):80. Oct 2 2017

73. Sheikhbahaei S, Jones CS, Porter KK, Rowe SP, Gorin MA, Baras AS, Pierorazio PM, Ball MW, Higuchi T, Johnson PT, Solnes LB, Epstein JI, Allaf ME, Javadi MS. Defining the Added Value of 99mTc-MIBI SPECT/CT to Conventional Cross-Sectional Imaging in the Characterization of Enhancing Solid Renal Masses. Clin Nucl Med.42(4):e188-e93. Apr 2017

74. Stoianovici D, Kim C, Petrisor D, Jun C, Lim S, Ball MW, Ross A, Macura KJ, Allaf M. MR Safe Robot, FDA Clearance, Safety and Feasibility Prostate Biopsy Clinical Trial. IEEE ASME Trans Mechatron.22(1):115-26. Feb 2017

75. Ball MW, Srinivasan R. Kidney cancer in 2017: Challenging and refining treatment paradigms. Nature reviews Urology.15(2):77-78. Feb 2018

76. Campbell SP, Baras AS, Ball MW, Kates M, Hahn NM, Bivalacqua TJ, Johnson MH, Pomper MG, Allaf ME, Rowe SP, Gorin MA. Low levels of PSMA expression limit the utility of (18)F-DCFPyL PET/CT for imaging urothelial carcinoma. Ann Nucl Med.32(1):69-74. Jan 2018

77. DiBianco JM, Gomella PT, Ball MW. Pathologic T3a renal cell carcinoma: a classification in need of further refinement. Ann Transl Med.6(Suppl 2):S133. Dec 2018

78. Ludwig WW, Wobker SE, Ball MW, Zysk AM, Yemul KS, Pierorazio PM, Gorin MA, Allaf ME. Margin Assessment in Renal Surgery Using a Handheld Optical Coherence Tomography Probe. Urology.113:241-45. Mar 2018

79. Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bosse D, Wankowicz SM, Cullen D, Horak C, Wind-Rotolo M, Tracy A, Giannakis M, Hodi FS, Drake CG, Ball MW, Allaf ME, Snyder A, Hellmann MD, Ho T, Motzer RJ, Signoretti S, Kaelin WG, Jr., Choueiri TK, Van Allen EM. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science.359(6377):801-06. Feb 16 2018

80. Tosoian JJ, Alam R, Ball MW, Carter HB, Epstein JI. Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy. Nature reviews Urology.15(1):55-66. Jan 2018

81. Baiocco JA, Ball MW, Pappajohn AK, Rayn KN, Bratslavsky G, Boyle SL, Linehan WM, Metwalli AR. A comparison of outcomes for standard and multiplex partial nephrectomy in a solitary kidney: The National Cancer Institute experience. Urol Oncol.37(6):356 e1-56 e7. Jun 2019

82. Ball MW. Editorial Comment. J Urol.201(6):1113. Jun 2019

83. Ball MW, Shuch BM. Inherited kidney cancer syndromes. Curr Opin Urol.29(4):334-43. Jul 2019

84. DiBianco JM, Gomella PT, Ball MW. Renal function after kidney surgery: "it's tough to make predictions, especially about the future". Ann Transl Med.7(Suppl 3):S82. Jul 2019

85. Gomella PT, Linehan WM, Ball MW. Salvage Surgery After Percutaneous Ablation of Renal Mass in Solitary Kidney in a Patient With Von Hippel-Lindau. Clin Genitourin Cancer.17(3):e482-e84. Jun 2019

86. Gomella PT, Shin P, Srinivasan R, Linehan WM, Ball MW. Obstructive azoospermia secondary to bilateral epididymal cystadenomas in a patient with von Hippel-Lindau. Urol Case Rep.27:100922. Nov 2019

87. Vocke CD, Ricketts CJ, Ball MW, Schmidt LS, Metwalli AR, Middelton LA, Killian JK, Khan J, Meltzer PS, Simonds WF, Merino MJ, Linehan WM. CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors. Urology.124:91-97. Feb 2019

88. Ball MW, An JY, Gomella PT, Gautam R, Ricketts CJ, Vocke CD, Schmidt LS, Merino MJ, Srinivasan R, Malayeri AA, Metwalli AR, Linehan WM. Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention. J Clin Oncol.38(11):1146-53. Apr 10 2020

89. Ball MW, Ricketts CJ. Complexities in estimating the true risk of hereditary leiomyomatosis and renal cell carcinoma and the development of kidney cancer. Cancer.126(16):3617-19. Aug 15 2020

90. Farhadi F, Nikpanah M, Paschall AK, Shafiei A, Tadayoni A, Ball MW, Linehan WM, Jones EC, Malayeri AA. Clear Cell Renal Cell Carcinoma Growth Correlates with Baseline Diffusion-weighted MRI in Von Hippel-Lindau Disease. Radiology.295(3):583-90. Jun 2020

91. Gomella PT, Sanford TH, Pinto PA, Bratslavsky G, Metwalli AR, Linehan WM, Ball MW. Long-term Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma. Urology.140:85-90. Jun 2020

92. Gurram S, Al Harthy M, Ball MW. The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update. Discov Med.29(158):191-99. May-Jun 2020

93. O'Connor LP, Lebastchi AH, Brems J, Wang AZ, Linehan WM, Ball MW. Salvage robotic transmesenteric off-clamp partial nephrectomy after multiple prior open kidney surgeries. Urol Case Rep.30:101135. May 2020

94. Ricketts CJ, Vocke CD, Lang M, Chen X, Zhao Y, Tran B, Tandon M, Schmidt LS, Ball MW, Linehan WM. A germline 1;3 translocation disrupting the VHL gene: a novel genetic cause for von Hippel-Lindau. J Med Genet. Oct 16 2020

95. Telfer SI, Ball MW. Editorial Comment. Urology.143:140-41. Sep 2020

96. Wei D, Yang Y, Ricketts CJ, Vocke CD, Ball MW, Sourbier C, Wangsa D, Wangsa D, Guha R, Zhang X, Wilson K, Chen L, Meltzer PS, Ried T, Thomas CJ, Merino MJ, Linehan WM. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments. Genes, chromosomes & cancer.59(8):472-83. Aug 2020

97. Yerram NK, Ball MW. Editorial Comment. Urology.144:156-57. Oct 2020

98. Bhambhvani HP, Daneshvar MA, Peterson DJ, Ball MW. Partial versus total adrenalectomy for pheochromocytoma: a population-based comparison of outcomes. Int Urol Nephrol. Oct 8 2021

99. Bratslavsky G, Mendhiratta N, Daneshvar M, Brugarolas J, Ball MW, Metwalli A, Nathanson KL, Pierorazio PM, Boris RS, Singer EA, Carlo MI, Daly MB, Henske EP, Hyatt C, Middleton L, Morris G, Jeong A, Narayan V, Rathmell WK, Vaishampayan U, Lee BH, Battle D, Hall MJ, Hafez K, Jewett MAS, Karamboulas C, Pal SK, Hakimi AA, Kutikov A, Iliopoulos O, Linehan WM, Jonasch E, Srinivasan R, Shuch B. Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer.127(21):3957-66. Nov 1 2021

100. Crooks DR, Maio N, Lang M, Ricketts CJ, Vocke CD, Gurram S, Turan S, Kim YY, Cawthon GM, Sohelian F, De Val N, Pfeiffer RM, Jailwala P, Tandon M, Tran B, Fan TW, Lane AN, Ried T, Wangsa D, Malayeri AA, Merino MJ, Yang Y, Meier JL, Ball MW, Rouault TA, Srinivasan R, Linehan WM. Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer. Science signaling.14(664). Jan 5 2021

101. Geynisman DM, Maranchie JK, Ball MW, Bratslavsky G, Singer EA. A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer. Urol Oncol.39(9):548-60. Sep 2021

102. Gomella PT, Linehan WM, Ball MW. Precision Surgery and Kidney Cancer: Knowledge of Genetic Alterations Influences Surgical Management. Genes (Basel).12(2). Feb 11 2021

103. Gurram S, Friedberg NA, Gordhan C, Li W, Ahdoot MA, Egan J, Yerram NK, Bratslavsky G, Metwalli AR, Linehan WM, Ball MW. Reoperative Partial Nephrectomy-Does Previous Surgical Footprint Impact Outcomes? J Urol.206(3):539-47. Sep 2021

104. Lang M, Vocke CD, Ricketts CJ, Metwalli AR, Ball MW, Schmidt LS, Linehan WM. Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma. Urology.149:89-97. Mar 2021

105. Lebastchi AH, Haynes B, Gurram S, Bratslavsky G, Metwalli AR, Linehan WM, Ball MW. X-Capsular Incision for Tumor Enucleation (X-CITE)-Technique: A Method to Maximize Renal Parenchymal Preservation for Completely Endophytic Renal Tumors. Urology.154:315-19. Aug 2021

106. Nikpanah M, Paschall AK, Ahlman MA, Civelek AC, Farhadi F, Mirmomen SM, Li X, Saboury B, Ball MW, Merino MJ, Srinivasan R, Jones EC, Linehan WM, Malayeri AA. (18)Fluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes. Abdom Radiol (NY).46(7):3301-08. Jul 2021

107. Nikpanah M, Xu Z, Jin D, Farhadi F, Saboury B, Ball MW, Gautam R, Merino MJ, Wood BJ, Turkbey B, Jones EC, Linehan WM, Malayeri AA. A deep-learning based artificial intelligence (AI) approach for differentiation of clear cell renal cell carcinoma from oncocytoma on multi-phasic MRI. Clin Imaging.77:291-98. Sep 2021

108. Owens-Walton J, Gurram S, Merino MJ, Linehan WM, Ball MW. Macronodular adrenal hyperplasia masquerading as an upper pole renal mass. Urol Case Rep.37:101603. Jul 2021

109. Sanford T, Gomella PT, Siddiqui R, Su D, An JY, Bratslavsky G, Ball MW, Linehan WM, Metwalli AR. Long term outcomes for patients with von Hippel-Lindau and Pheochromocytoma: defining the role of active surveillance. Urol Oncol.39(2):134 e1-34 e8. Feb 2021

110. Vocke CD, Ricketts CJ, Schmidt LS, Ball MW, Middelton LA, Zbar B, Linehan WM. Comprehensive characterization of Alu-mediated breakpoints in germline VHL gene deletions and rearrangements in patients from 71 VHL families. Hum Mutat.42(5):520-29. May 2021

112. Yang Y, Ricketts CJ, Vocke CD, Killian JK, Padilla-Nash HM, Lang M, Wei D, Lee YH, Wangsa D, Sourbier C, Meltzer PS, Ried T, Merino MJ, Metwalli AR, Ball MW, Srinivasan R, Linehan WM. Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. Genes, chromosomes & cancer.60(6):434-46. Jun 2021